Lyra Therapeutics Inc.

NASDAQ: LYRA · Real-Time Price · USD
6.93
-0.17 (-2.39%)
At close: Aug 15, 2025, 12:36 PM

Lyra Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
1.53M 1.56M 1.36M 285K
Cost of Revenue
n/a 48.03M 1.07M 29.69M
Gross Profit
1.53M 1.56M 296K -716K
Operating Income
-96.35M -67.12M -56.31M -43.62M
Interest Income
2.95M 4.5M 1.04M 102K
Pretax Income
-93.4M -62.62M -55.27M -43.51M
Net Income
-93.44M -62.68M -55.28M -43.51M
Selling & General & Admin
18.5M 19.06M 17.56M 14.21M
Research & Development
43.77M 48.03M 38.8M 29.69M
Other Expenses
-471K -46.44M -37.48M -1M
Operating Expenses
61.8M 20.65M 18.87M 42.9M
Interest Expense
n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
97.88M 68.68M 57.67M 43.9M
Income Tax Expense
39K 59K 13K n/a
Shares Outstanding (Basic)
65.11M 49.75M 30.24M 12.99M
Shares Outstanding (Diluted)
65.11M 49.8M 30.24M 12.99M
EPS (Basic)
-1.43 -1.26 -1.83 -3.35
EPS (Diluted)
-1.43 -1.26 -1.83 -3.35
EBITDA
-60.26M -65.25M -53.92M -42.61M
EBIT
-60.73M -65.53M -54.99M -43.62M
Depreciation & Amortization
471K 278K 1.07M 1M